Check Out Our CD40 mAb Phase II Poster at ASCO2024!

Check Out Our CD40 mAb Phase II Poster at ASCO2024!

ASCO 2024 | Biocytogen/Eucure Biopharma to Present Two Phase II Clinical Studies of CD40 Agonistic Antibody YH003


Biocytogen’s wholly owned subsidiary Eucure Biopharma today announced that the company will present two phase II clinical studies of YH003, a humanized anti-CD40 agonistic monoclonal antibody, at the American Society of Clinical Oncology (ASCO) annual meeting, taking place in Chicago, US, from May 31-June 4, 2024.


Poster Session:

Title: A phase II, multicenter, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC)

Clinical Trial Registration Number: NCT05031494

Abstract Number: 4146

Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track: Pancreatic Cancer – Advanced/Metastatic Disease

Poster Bd #: 126

Date and Time: 13:30-16:30 CDT, June 1, 2024

Location: Hall A


Publication Only:

Title: A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma

Clinical Trial Registration Number: NCT05420324

Abstract Number: e21520

Track: Melanoma/Skin Cancers

Sub Track: Advanced/Metastatic Disease


About YH003

YH003 is a humanized IgG2 agonistic anti-CD40 monoclonal antibody independently developed by Biocytogen/Eucure Biopharma. Based on the safety, efficacy, and PK data from the previous phase I study, the recommended phase II dose (RP2D) of YH003 was identified as 0.3 mg/kg. The combination of YH003 and Toripalimab has shown encouraging anti-tumor activity in patients with advanced solid tumors.

Download YH003 Phase I Poster


Preclinically, YH003, whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, demonstrated strong anti-tumor effects in multiple tumor models in Biocytogen’s humanized CD40 mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.

At AACR2024, our collaborator Syncromune revealed initial clinical data of SYNC-T SV-102, which includes YH003 and our clinical-stage CTLA-4 monoclonal antibody YH001. SYNC-T SV-102 demonstrated a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Learn More About SYNC-T SV-102


Interested in learning more about our YH003 mAb? Contact us today for partnership opportunities!

Contact Us




Event Date: May 8-10, 2024 | Event Location: Seoul, South Korea


Back to top